Hong Kong-listed Brii expects to launch Covid-19 drug as early as January, eyes revenue generation

//Hong Kong-listed Brii expects to launch Covid-19 drug as early as January, eyes revenue generation

Hong Kong-listed Brii expects to launch Covid-19 drug as early as January, eyes revenue generation

Brii Biosciences, a multinational biotechnology firm listed in Hong Kong, plans to launch its Covid-19 drug in China next year.The drug, the first of its kind to be approved in China, was going through an additional government review before a likely launch in the first quarter of 2022, Hong Zhi, the company’s CEO and co-founder, said in an interview. Hong Kong was also showing interest in the antibody therapy, he added.“China has done a great job in terms of isolation, quarantining and testing,…

Article by [author-name] (c) Business - South China Morning Post - Read full story here.

By | 2021-12-28T00:30:11+00:00 December 28th, 2021|Business|Comments Off on Hong Kong-listed Brii expects to launch Covid-19 drug as early as January, eyes revenue generation